TMO Research Update — September 18, 2026
Updated Thesis
Thermo Fisher Scientific is a global life-sciences and laboratory-services platform spanning Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services, with recognized brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Patheon, and PPD, serving pharmaceutical, biotech, clinical, academic, and government customers through a 125,000-person organization. Business quality is high: TTM gross margin of 40.4%, TTM operating margin of 17.7%, TTM net margin of 15.1%, ROE of 13.4%, and free cash flow of $19.73 per share on revenue of $124.69 per share demonstrate a durable, cash-generative franchise with a broad consumables, instruments, and services mix. Growth is steady rather than explosive, with revenue up 10.5% and earnings up 7.4% in the most recent quarter, placing the company in a scaling phase.
The investment grade as of this refresh is B — solid business quality. A-tier business, B-tier valuation with 31.1% upside to blended fair value but no specific near-term catalyst.
Key Metrics at a Glance
- Revenue growth: +10.5% year over year
- Net margin: 15.1%
- Fair value upside: +31.1% to our estimate of $863
Current price: $658.32
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Thermo Fisher Scientific Inc. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full TMO research →](/stocks/TMO)